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High expression of thymidylate synthase (TS) and inactivation of p53 are allegedly associated with chemoresistance. The authors
evaluated TS and p53 expression in gastric cancer treated with neoadjuvant S-1/cisplatin chemotherapy. Paraffin sections of
pretreatment biopsy and surgical specimens from 41 gastric cancers were immunostained for TS and p53 protein after appropriate
antigen retrieval. Fifty-one cases without neoadjuvant chemotherapy were also studied. In the pretreatment biopsies, high expression
of TS was seen in 8% of the histologic responders, in 28% of the nonresponders and in 31% of the controls. High expression of p53
was observed in 56% of the nonresponders, but in 8% of the responders and in 29% of the controls (Po0.01 and Po0.05,
respectively). The TS- and/or p53-high phenotype was seen in 76% of the nonresponders and in 54% of the controls, but in 8% of the
responders (Po0.0001 and Po0.005, respectively). The data of the surgical specimens were consistent with those of the
pretreatment biopsies. These results suggest that immunostaining for TS and p53 protein is useful for pretreatment selection of
gastric cancer patients unresponsive to S-1/cisplatin chemotherapy.
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Gastric cancer is declining in incidence, but it remains a significant
cause of mortality (Parkin et al, 1988). Resectability is one of the
most important prognostic factors in treating gastric cancer (Yeh
and Cheng, 2004). Even in resectable tumours, the recurrence rate
is significantly high. For downstaging and lowering the rate of
postoperative recurrence, neoadjuvant chemotherapy for gastric
cancer has been performed in the high-risk group (Yonemura et al,
1996; Yeh and Cheng, 2004). It has been reported that histological
grading is a useful prognostic indicator in gastric cancer treated
with neoadjuvant chemotherapy (Yonemura et al, 1996).
Fluoropyrimidines (5-fluorouracil (5-FU) and its prodrugs) are
most widely used for the treatment of solid tumours including
gastric cancer. Several kinds of fluoropyrimidines are now in use.
S-1 is a novel fluoropyrimidine consisting of tegafur, 5-chloro-2,
4-dihydroxypyrimidine (CDHP, a strong inhibitor of dihydro-
pyrimidine dehydrogenase, 5-FU-catabolizing enzyme) and potas-
sium oxonate with a molar ratio of 1:0.4:1 (Malet-Martino and
Martino, 2002). S-1, especially in combination with cisplatin,
shows a promising effectiveness with acceptable toxicities against
gastric, pancreatic and non-small-cell lung cancers (Schoffski,
2004; Yoshida et al, 2005).
Analysis of the predictors for identifying patients who will be
sensitive or resistant to chemotherapeutic agents is one of the
approaches for individualizing the treatment. The appropriate
decision for chemotherapy leads to the avoidance of unpleasant
side effects. At the present time, however, there are no clinically
accepted markers that can accurately predict the sensitivity or
resistance of gastric cancer against chemotherapeutic agents.
Thymidylate synthase (TS) is the target enzyme of 5-FU, and
the inhibition of TS activity is the principal mechanism of its
cytotoxicity. Plural preclinical studies have suggested that high TS
levels are closely associated with the 5-FU resistance of cancer cells
(Beck et al, 1994; Peters et al, 1994). Investigators have reported
the clinical relevance of high TS mRNA as a predictor of the
resistance to 5-FU/cisplatin or S-1 in gastric cancer (Lenz et al,
1996; Ichikawa et al, 2004). However, the relationship between
immunohistochemical expression of TS in pretreatment biopsy
specimens of gastric cancer and the response to fluoropyrimidine-
based chemotherapy has revealed conflicting results. Some
investigators have shown that the TS expression in gastric cancer
is of limited value in predicting the clinical response to
fluoropyrimidine-based chemotherapy (Boku et al, 1998; Miya-
moto et al, 2000). In contrast, there is a report demonstrating the
clinical relevance of high TS expression as a predictor of the
resistance to fluoropyrimidine-based chemotherapy and the short
survival of the patients (Yeh et al, 1998).
The product of the tumour-suppressor gene, p53, is a pleiotropic
molecule with plurifunctions. p53 protein normally functions as
either a repair initiator of the damaged sense DNA or a trigger of
the apoptotic pathway if a sufficient level of damage takes place
within the cell (Leonard et al, 1995; Harwood et al, 1996). It has
been demonstrated that p53-dependent apoptosis is associated
with the cytotoxic effects of cisplatin or 5-FU plus cisplatin for
gastric cancer cells (Ikeguchi et al, 1997; Satomi et al, 2002;
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sMatsuhashi et al, 2004). The absence of wild-type p53 function
results in the cellular resistance to anticancer agents such as 5-FU
and cisplatin in several cell lines, including gastric cancer (Nabeya
et al, 1995; Harris, 1996). In addition, several investigators have
demonstrated the correlation between the immunohistochemical
overexpression of p53 in primary gastric cancer and the resistance
to cisplatin-contained regimens (Hamada et al, 1996; Cascinu et al,
1998; Nakata et al, 1998).
There is evidence that TS forms a ribonucleoprotein complex
with p53 mRNA (Liu et al, 2002). It is thereby suggested that TS
may play a critical role in regulating the cell cycle and the process
of apoptosis through its regulatory effects on the expression of
p53. In the present study, we immunohistochemically analysed the
relationship between the expression of TS and p53 and the effects
of neoadjuvant S-1/cisplatin chemotherapy for gastric cancers.
We demonstrate here that TS- and/or p53-high expression can be a
relevant and useful predictor in determining S-1/cisplatin resis-
tance of gastric cancer.
MATERIALS AND METHODS
Patients and specimens
Table 1 summarizes pretreatment clinicopathological features of
92 patients included in the present study. All the patients were
treated for advanced gastric cancer between 2001 and 2006 at the
Department of Surgery, Fujita Health University Hospital,
Toyoake, Japan. Forty-one patients were preoperatively treated
with the combination of S-1 (80–120mgm
 2 per day for 4 weeks)
and cisplatin (35mgm
 2 on day 8). One cycle of this regimen was
completed in 6 weeks and the next cycle of this regimen was
started after 2 weeks off of S-1 administration since the last day
of the S-1 administration. At least two cycles of this regimen were
performed, depending on the clinical status of these patients. The
median of this regimen was consequently two cycles. We have
adopted the dose of 35mgm
 2 on day 8 of cisplatin, because of the
fact that S-1 alone and/or S-1 plus low-dose cisplatin must have
caused a significant clinical effect. We have experienced cases
showing a significant clinical effect after S-1 alone and/or S-1 plus
low-dose cisplatin in neoadjuvant settings (Yoshida et al, 2005).
Fifty-one patients who did not receive neoadjuvant chemotherapy
were also analysed as controls. The two groups were closely
matched and there were no differences in the clinicopathological
backgrounds. The present study was approved by the institutional
ethical review board for human investigation at Fujita Health
University.
Pretreatment biopsy specimens and surgically resected tumours
were routinely fixed in 10% formalin and embedded in paraffin
wax. Sections, 3mm thick, were cut and mounted on aminopropyl-
triethoxysilane slides, and stained with haematoxylin and eosin
(HE), in order to assess histopathological features and the
responsiveness to neoadjuvant chemotherapy under a light
microscope.
Histological assessment of chemotherapeutic effects
Chemotherapeutic effects were histologically evaluated using the
surgical specimens, according to the Japanese Classification of
Gastric Carcinoma (Japanese Research Society for Gastric Cancer,
1999). Major grading (grades 0–3) and additional minor grading
for grade 1 (grades 1a and b) were used, based upon the degree of
necrosis or disappearance of tumour cells in the lesion; grade 0: no
change, grade 1: mild change (grade 1a: necrosis or disappearance
of the tumour seen in less than 1/3 of the entire cancer area, which
is regarded as undistinguishable from spontaneous tumour
necrosis; and grade 1b: necrosis or disappearance of the tumour
seen in more than 1/3 but less than 2/3 of the entire cancer area),
grade 2: moderate change (necrosis or disappearance of the
tumour seen in more than 2/3 of the entire cancer area, but still
with remaining viable tumour cells) and grade 3: severe change (no
viable tumour cells remain). The patients with grades 1b and 2
were categorised as the histologic responders, and the patients
with grades 0 and 1a as the histologic nonresponders. No grade 3
case was observed.
Immunohistochemistry
In addition to pretreatment biopsy specimens, one or two
representative paraffin blocks of the resected tumour were chosen
for immunohistochemical analysis. The sections were deparaffi-
nised with xylene and rehydrated with graded ethanols. Endo-
genous peroxidase was inactivated by 0.03% hydrogen peroxide in
methanol for 30min. Heat-induced epitope retrieval was applied
using a pressure cooker (Delicio 6L; T-FAL, Rumily, France) for
10min. Optimal soaking solutions, determined by preliminary
experiments (Kamoshida et al, 2003a,b), were selected for the
respective markers: 1mM ethylenediaminetetraacetic acid solution,
pH 8.0 for TS and 10mM citrate buffer, pH 7.0 for p53. After
pressure-cooking, the sections were left at room temperature for
cooling in the soaking solution for 30min.
The sections were then incubated with the primary antibody that
reacts specifically with TS (rabbit polyclonal, 1:200 dilution; Taiho
Pharmaceutical Co., Tokushima, Japan) or p53 (mouse mono-
clonal, clone DO-7, 1:200 dilution; Dako Co., CA, USA), overnight
at room temperature. Histofine Simple Stain MAX-PO (Nichirei,
Tokyo, Japan), employing the universal immunoperoxidase poly-
mer method, was utilised as a second-layer reagent. The reaction
products were visualised in 50mgdl
 1 3,30-diaminobenzidine
tetrahydrochloride solution containing 0.003% hydrogen peroxide.
The nuclei were lightly counterstained with Mayer’s haematoxylin.
Negative control studies were performed without applying the
primary antibodies. Sections known to be stained positively were
included in each run as positive staining controls.
Evaluation of immunostaining
The HE-stained and immunostained sections were independently
reviewed by two investigators (SK and MS), without prior
knowledge of clinical data of the patients. Thymidylate synthase
Table 1 Pretreatment clinicopathological features of 41 patients treated
with neoadjuvant chemotherapy and 51 control patients
Clinicopathological
features
Patients treated
with neoadjuvant
chemotherapy
(n¼41)
Control patients
(n¼51)
Age (years)
o60 15 17
X60 26 34
Gender
Male 27 33
Female 14 18
Primary site
Cardia 11 12
Fundus 20 26
Antrum 10 13
Histologic type
a
Intestinal 16 19
Diffuse 22 29
aPretreatment biopsy specimens were available for analysis in 38 out of 41 patients
with neoadjuvant chemotherapy, and 48 out of 51 control patients without
neoadjuvant chemotherapy.
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sexpression was classified into two groups in a semiquantitative
manner: ‘low’ expression (negative or positive in 50% or less of
tumour cells) vs ‘high’ expression (positive in more than 50% of
tumour cells). Most of the other investigators defined TS
expression of 25–30% as a threshold level (Yeh et al, 1998;
Miyamoto et al, 2000). The reason for the difference is explained as
follows: (1) to the best of our belief, TS staining method employed
in our study is very sensitive, suitable and reproducible
(Kamoshida et al, 2003a); (2) in our previous studies using
colorectal cancer specimens, 30% was defined as a threshold level
of TS expression (Kamoshida et al, 2003b, 2004). It has been
reported that the mean TS mRNA level in gastric cancers is 1.6- to
1.7-fold higher than that in colorectal cancers, and the TS mRNA
level is closely correlated with immunohistochemical expression of
TS (Johnston et al, 1995; Uchida et al, 2001).
The pattern of immunohistochemical expression of p53 protein,
the proportion of p53-positive cells, must be very important in
discussing the relationship between p53 protein expression and
gene mutation (Hall and Lane, 1994). The occurrence of occasional
positive cells does not seem to correlate with obvious abnormality
of p53 gene, but the positive staining in the majority of cells is
frequently associated with gene mutation (Baas et al, 1994; Shiao
et al, 2000). For p53, thus, negative or positive staining in 70% or
less of tumour cells was considered ‘low’ expression, and positive
staining in more than 70% of tumour cells was ‘high’ expression.
According to the principle of imunohistochemical evaluation using
multiple clinical samples, the intensity of staining should not be
considered for the judgement of positivity (Kamoshida et al, 2004).
The evaluation of biopsy specimens was regarded appropriate
when two or more biopsy pieces were available, as reported
previously (Kamoshida et al, 2003b).
Statistical analysis
The Fisher’s exact probability test was employed for determining
the statistical significance of correlations between the marker
expression and histological chemotherapeutic effects. P-values
o0.05 were considered statistically significant.
RESULTS
Marker expression
Thymidylate synthase immunoreactivity was observed in the
cytoplasm of cancer cells. p53 protein was invariably localized in
the nuclei. Little difference in the staining pattern of TS and p53
was seen between invasive and noninvasive components within the
same tumours. Epithelial cells located in the generative zone of
normal gastric mucosa and in the basal half of intestinal
metaplastic mucosa were consistently immunoreactive for TS. In
addition, TS was expressed in such nonepithelial cells as germinal
centre lymphocytes, plasma cells, endothelial cells, fibroblasts and
smooth muscle cells. No apparent p53 expression was detected in
the non-neoplastic tissue and cells.
Chemotherapeutic effects and marker expression in
pretreatment biopsy specimens
Histological chemotherapeutic responders consisted of 15 (37%)
out of 41 cases (grade 1b: six cases and grade 2: nine cases), and
the remaining 26 (63%) were categorised as the nonresponders
(grade 0: eight cases and grade 1a: 18 cases).
Table 2 shows the relationship between chemotherapeutic effects
and marker expression in the pretreatment biopsy specimens.
Adequate biopsy material obtained from two cancerous parts or
more was available in 38 out of the 41 cases receiving neoadjuvant
chemotherapy and in 48 out of the 51 control untreated cases. High
TS expression was observed in one lesion (8%) of 13 responders, in
seven lesions (28%) of 25 nonresponders and in 15 lesions (31%)
of 48 control untreated cases: no significant differences were
noted.
High expression of p53 was observed in 14 lesions (56%) of the
nonresponders and in 14 lesions (29%) of the control cases, but in
one lesion (8%) of the responders: there was significant difference
between the responders and the nonresponders (Po0.01), and
between the nonresponders and the control cases (Po0.05).
Accuracy of the p53 expression for predicting chemoresistance was
68%; 26 (12 responders and 14 nonresponders) out of 38 patients
treated with neoadjuvant chemotherapy.
The TS- and/or p53-high phenotype was demonstrated in 19
lesions (76%) of the nonresponders and 26 lesions (54%) of the
control cases, but in one lesion (8%) of the responders: the
differences between the responders and the nonresponders or the
control cases were statistically significant (Po0.0001 and
Po0.005, respectively). Accuracy of the combination of TS and
p53 expression for predicting chemoresistance was 82%; 31 (12
responders and 19 nonresponders) out of 38 patients treated with
neoadjuvant chemotherapy. Representative immunostaining pat-
terns in the pretreatment biopsy specimens are shown in Figures 1
and 2.
Chemotherapeutic effects and marker expression in
surgically resected tumours
Table 3 shows the relationship between chemotherapeutic effects
and marker expression in the surgical specimens. The data of the
Table 2 Relationship between expression of TS and p53, and effects of neoadjuvant S-1/cisplatin chemotherapy in pretreatment biopsy specimens
Marker expression
Histological
responders (%)*
(n¼13)
a
Histological non-
responders (%)**
(n¼25)
a
Control untreated
cases (%)*** (n¼48)
a
P-value
* vs ** * vs *** ** vs ***
TS
High 1 (8) 7 (28) 15 (31) 0.22 0.15 40.99
Low 12 (92) 18 (72) 33 (69)
p53
High 1 (8) 14 (56) 14 (29) o0.01
b 0.16 o0.05
b
Low 12 (92) 11 (44) 34 (71)
TS- and/or p53-high 1 (8) 19 (76) 26 (54) o0.0001
b o0.005
b 0.08
TS- and p53-low 12 (92) 6 (24) 22 (46)
aPretreatment biopsy specimens were available for analysis in 38 out of 41 patients with neoadjuvant chemotherapy, and 48 out of 51 control patients without neoadjuvant
chemotherapy.
bStatistically significant. *Responders, **Non-responders, ***Control cases.
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ssurgical specimens were consistent with those of the pretreatment
biopsies. High expression of TS was seen in one lesion (7%) of 15
responders, in seven lesions (27%) of 26 nonresponders and in 14
lesions (27%) of 51 control untreated cases: no significant
differences were detected. High expression of p53 was detected
in 14 lesions (54%) of the nonresponders, but in one lesion (7%) of
     
ABC D
Figure 1 The pretreatment biopsy specimen (A–C) and the resected tumour (D) from a representative gastric cancer, which responded to neoadjuvant
S-1/cisplatin chemotherapy. (A, D): HE staining, (B): TS immunoreactivity, (C): p53 immunoreactivity. Chemotherapy-induced histological changes including
the disintegration of glandular structures with marked inflammatory cell infiltration is noted in the resected tumour when compared with the pretreatment
biopsy specimen. The cytoplasm of only a few cancer cells (arrow) and plasma cells (arrowhead) in the stroma are positive for TS. There are no p53-positive
cells.
ABCD
EFGH
Figure 2 The pretreatment biopsy specimen (A–C, E–G) and the resected tumour (D, H) from two representative gastric cancers, which did not
respond to neoadjuvant S-1/cisplatin chemotherapy. (A, D, E, H): Haematoxylin and eosin staining, (B, F): TS immunoreactivity, (C, G): p53
immunoreactivity. Little histological changes are discernible after chemotherapy. In a case shown in the top panels (A–D), a number of cancer cells express
both TS and p53. In another case shown in the bottom panels (E–H), TS is expressed in a number of cancer cells. p53-positive nuclei are heterogeneously
observed. Plasma cells in the stroma (arrows) are also immunoreactive for TS.
Table 3 Relationship between expression of TS and p53, and effects of neoadjuvant S-1/cisplatin chemotherapy in surgically resected tumours
Marker expression
Histological
responders (%)*
(n¼15)
Histological non-
responders (%)**
(n¼26)
Control untreated
cases (%)*** (n¼51)
P-value
* vs ** * vs *** ** vs ***
TS
High 1 (7) 7 (27) 14 (27) 0.22 0.16 40.99
Low 14 (93) 19 (73) 37 (73)
p53
High 1 (7) 14 (54) 15 (29) o0.005
a 0.09 o0.05
a
Low 14 (93) 12 (46) 36 (71)
TS- and/or p53-high 1 (7) 19 (73) 26 (51) o0.0001
a o0.005
a 0.09
TS- and p53-low 14 (93) 7 (27) 25 (49)
aStatistically significant. *Responders, **Non-responders, ***Control cases.
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sthe responders and in 15 lesions (29%) of the control cases: The
statistical significance was noted between the responders and the
nonresponders (Po0.005), and between the nonresponders and
the control cases (Po0.05). The TS- and/or p53-high phenotype
was observed in 19 lesions (73%) of the nonresponders and
26 lesions (51%) of the control cases, but in one lesion (7%) of the
responders: The differences between the responders and the
nonresponders or the control cases were statistically significant
(Po0.0001 and Po0.005, respectively).
Correlation of TS and p53 expression between
pretreatment biopsy specimens and surgically resected
materials
Table 4 demonstrates the concordance rate of TS and p53
expression between the pretreatment biopsy specimens and the
resected materials. Thymidylate synthase expression was concor-
dant in 34 (89%) out of 38 cases treated with neoadjuvant
chemotherapy and in 41 (85%) out of 48 control untreated cases.
The concordance of p53 expression was noted in 37 (97%) of the
cases treated with neoadjuvant chemotherapy and in all of the
control cases.
DISCUSSION
To our knowledge, the present study is an initial attempt to predict
the effects of S-1/cisplatin chemotherapy by the combination of TS
and p53 immunostaining in gastric cancer. Thymidylate synthase,
a critical target for fluoropyrimidines, catalyses the methylation of
deoxyuridine monophosphate to deoxythymidine monophosphate,
an essential step in DNA biosynthesis (Malet-Martino and
Martino, 2002). When the pretreatment biopsy specimens were
analysed, high expression of TS was observed in 8% of the
responders and in 28% of the nonresponders, without significant
difference. Yeh et al (1998) reported that high expression of TS
significantly predicted the resistance to high dose 5-FU and
leucovorin and the short survival of the patients, but others failed
to demonstrate the significant relationship between the TS expre-
ssion and the effects of fluoropyrimidine-based chemotherapy
(Boku et al, 1998; Miyamoto et al, 2000). These results suggest that
the effects of fluoropyrimidine-based chemotherapy for gastric
cancers are unable to be predicted by TS alone.
p53 participates in apoptotic pathways following treatment with
DNA-damaging agents such as cisplatin (Ikeguchi et al, 1997;
Satomi et al, 2002; Matsuhashi et al, 2004), and inactivation of
the p53 gene contributes to the resistance to anticancer agents in
several cell lines, including gastric cancer (Nabeya et al, 1995;
Harris, 1996). Fifteen years ago, a series of important issues were
raised concerning the immunohistochemical assessment of p53
protein (Wynford-Thomas, 1992). Of particular note was that
immunohistochemically detected p53 protein expression did not
necessarily indicate the presence of p53 genetic mutations. The
pattern of immunohistochemical expression of p53 protein,
the proportion of p53-positive cells, should be crucial in discussing
the relationship between p53 immunoreactivity and genetic
mutation (Hall and Lane, 1994). For example, focal (hetero-
geneous) expression, the occurrence of dispersed positive cells,
does not seem to correlate with the obvious abnormality of p53
gene (Baas et al, 1994; Shiao et al, 2000). It may rather reflect an
accumulation of wild-type p53 protein as a result of either a
response to DNA damage, alterations in the normal degradation
process, or the stabilization of the gene product by an interaction
with viral or cellular proteins (Baas et al, 1994; Kirsch and Kastan
1998). In contrast, diffuse (homogeneous) expression, the positive
staining in the majority of cells, is frequently associated with
mutation (Baas et al, 1994; Shiao et al, 2000). This view is
supported by the clinical data, in which the differences in
expression patterns are significantly correlated with the patient’s
prognosis (Barnes et al, 1993; Shiao et al, 2000). In addition, the
intensity of staining should not be considered for the judgment of
staining results, according to the principle of immunohistochem-
ical evaluation using multiple clinical samples (Kamoshida et al,
2004). Still, it remains possible that there might be some
discordance between p53 immunoreactivity and the genetic
abnormality: for example, the presence of missing deletions may
result in the abolishment of protein production, and some point
mutations may lead to the production of unstable proteins without
an increase of the half-life (Wynford-Thomas, 1992).
In the present study, p53 expression was classified into two
groups: low expression (negative or nuclear positivity in p70% of
tumour cells) vs high expression (nuclear positivity in 470% of
tumour cells). High expression of p53 in the pretreatment biopsy
specimen was observed in 56% of the nonresponders but in 8% of
the responders (Po0.01). These results let us postulate that the
high expression of p53 protein in our series may reflect the diffuse
(homogenous) overexpression of the mutant-type protein, leading
to the resistance to S-1/cisplatin chemotherapy. However, this
must be confirmed by additional study using molecular assays,
such as single-strand conformational polymorphism analysis and
direct sequencing.
When we analysed the combination of TS and p53 expression in
the pretreatment biopsy, TS- and/or p53-high phenotype was seen
in 76% of the nonresponders but in 8% of the responders
(Po0.0001). Accuracy predicting the chemoresistance to S-1/
cisplatin was 82% when p53 expression was combined with TS
expression, whereas it was 68% when only p53 expression was
applied. These results indicate that the TS- and/or p53-high
phenotype as determined by immunohistochemistry is a strong
predictor of the resistance to S-1/cisplatin chemotherapy. Report-
edly, TS forms a ribonucleoprotein complex with the p53 mRNA
and the functional consequence of the binding is translational
repression (Liu et al, 2002). In the lesions showing p53-low but TS-
high phenotype (observed in five lesions of the nonresponders but
in none of the responders), thus, TS may play a critical role in
regulating the process of apoptosis through its regulatory effects
on expression of p53.
We demonstrated acceptable consistency in TS and p53
expression between the pretreatment biopsy specimens and
surgically resected materials. The results suggest that the expres-
Table 4 Correlation of TS and p53 expression between pretreatment
biopsy specimens and surgically resected materials
Resected tumour
Pretreatment biopsy High Low Concordance (%)
Cases treated with neoadjuvant chemotherapy (n¼38)
TS
High 6 2 34 (89%)
Low 2 28
p53
High 14 1 37 (97%)
Low 0 23
Control untreated cases (n¼48)
TS
High 11 4 41 (85%)
Low 3 30
p53
High 14 0 48 (100%)
Low 0 34
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ssion of TS and p53 protein is hardly changed after S-1/cisplatin
chemotherapy, and immunostaining of TS and p53 in pretreatment
biopsy specimens can be utilised for predicting the chemoresis-
tance to S-1/cisplatin. Discrepant results of TS were probably due
to the heterogenous distribution seen in most cancer tissues. In
vitro study has demonstrated that twice the amount of TS is
observed in gastric cancer cells after continuous exposure to 5-FU,
when compared to the untreated cells (Yukimoto et al, 2001).
However, the TS induction after drug exposure has not been
documented in gastric cancer patients undergoing fluoropyrimi-
dine-based chemotherapy (Uchida et al, 2001). A similar
discrepancy between in vitro and in vivo systems has found in
colorectal cancer (Peters et al, 2000; Uchida et al, 2001; Kamoshida
et al, 2003b).
In conclusion, we demonstrated that high expression of TS and/
or p53 in the pretreatment biopsy specimens predicted the
chemoresistance to S-1 plus cisplatin in gastric cancer. We believe
that the data of the present retrospective study provide with the
basis for a prospective study, in which immunohistochemical
expression of TS and p53 is utilised as a weapon for tailor-made
chemotherapy.
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